Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
Kantonsspital Baselland to deploy the AI-powered platform, helping pathologists improve accuracy and efficiency during primary cancer diagnosis
Tel Aviv, Israel, and Basel, Switzerland, Nov 3, 2021 – Ibex Medical Analytics, the pioneer in artificial intelligence (AI) -powered cancer diagnostics and Kantonsspital Baselland, a healthcare provider in Northwestern Switzerland, today announced the first deployment in Switzerland of an AI solution supporting pathologists during routine cancer diagnosis.
Pathologists play a crucial role in the detection and diagnosis of disease, with their assessments being vital for reaching correct treatment decisions by oncologists. However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity, which significantly increases pathologists’ workloads. As pathology labs transition towards digital solutions, pathologists can implement AI-enhanced workflows to improve quality and efficiency of cancer diagnosis, resulting in better patient care.
Ibex transforms cancer diagnosis by harnessing AI and machine learning technology at an unprecedented scale. Ibex’s platform helps pathologists improve the quality of cancer diagnosis, reduce diagnosis time, boost productivity1, and implement real-time quality control2. It is CE marked for breast and prostate cancer detection in multiple workflows and was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Ibex has already demonstrated outstanding outcomes in clinical studies3,4 and deployed in labs worldwide where it is used as part of everyday clinical practice.
Kantonsspital Baselland (KSBL) is a hospital providing histological and molecular integrative cancer diagnostics and personalized care for tumor patients. KSBL have digitized their pathology services using Philips’ IntelliSite Pathology Solution, deploying a network of high-throughout digital pathology scanners, as well as an image management solution and an internally developed lab information system. As part of the AI deployment, pathologists at KSBL will use the AI platform, enabling them to streamline workflows and improve accuracy during primary diagnosis via automated case prioritization, cancer heatmaps, grading and other productivity-enhancing tools.
“Timely diagnosis delivered with the utmost quality are a cornerstone of cancer care at Kantonsspital Bselland, and we are committed to continually improving the technology and processes in our lab,” said Kirsten Mertz MD, Professor of Pathology at KSBL. “We were among the pioneers in adopting digital pathology in Switzerland and take special pride in being the first hospital in the country to implement artificial intelligence in pathology. We were impressed with the performance demonstrated by Ibex’s AI technology across multiple clinical studies in Europe and the United States and look forward to getting hands on experience in working with their solution and examining how it can help improve patient care.”
“We are thrilled to team up with Kantonsspital Baselland and enable their pathologists to use state-of-the-art AI-powered solutions to more accurately detect cancer and improve quality and efficiency of diagnosis,” said Stuart Shand, Chief Commercial Officer at Ibex Medical Analytics. “With this cooperation, KSBL sets a new standard in cancer care quality, further proving its leadership and commitment to its patients by deploying an advanced clinical-grade AI solution to ensure the best possible outcomes. artificial intelligence and digital pathology technologies become an essential part of cancer care programs, their adoption being a vision shared by both KSBL and Ibex.”Back